Status:
UNKNOWN
Vancomycin Prophylaxis in Recurrent Clostridium Difficile Infection
Lead Sponsor:
Corewell Health West
Conditions:
Clostridium Difficile Infection
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
We are doing this research study to determine if taking vancomycin in addition to a broad-spectrum antibiotic will decrease the chance of developing recurrent Clostridium difficile infection.
Detailed Description
To determine whether prophylactic use of oral vancomycin reduces the incidence of recurrent Clostridium difficile infection (RCDI) in hospitalized patients admitted from their home or another health c...
Eligibility Criteria
Inclusion
- In patients \>19 years of age
- History of C. difficile diarrhea within 16 weeks and treated with Flagyl or Vancomycin during last episode.
- Patients started on antibiotics during current admission for any other indication at any point of time during hospital course.
Exclusion
- Current diagnosis of CDI
- First episode of CDI during this admission.
- Allergy to Vancomycin or other known intolerance
- Pregnant
- h) Patient has received broad-spectrum antibiotics for more than 48 hours for this admission j) Incarceration
Key Trial Info
Start Date :
August 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 1 2016
Estimated Enrollment :
140 Patients enrolled
Trial Details
Trial ID
NCT02237859
Start Date
August 1 2014
End Date
August 1 2016
Last Update
September 11 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Spectrum Health Hospital
Grand Rapids, Michigan, United States, 49503